Alnylam Pharma (ALNY) Tops Q1 EPS by 11c
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.64), $0.11 better than the analyst estimate of ($1.75). Revenue for the quarter came in at $177.6 million versus the consensus estimate of $168.74 million.
2021 Financial Guidance
Full year 2021 financial guidance is reiterated and consists of the following:
Combined net product revenues for ONPATTRO, |
|
$610 million - $660 million | |
Net revenues from collaborations and royalties |
| $150 million - $200 million | |
GAAP R&D and SG&A expenses |
| $1,335 million - $1,455 million | |
Non-GAAP R&D and SG&A expenses* |
| $1,175 million - $1,275 million |
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.